We deliver quantitative, regulatory aligned dosimetry using predictive human dosimetry from pre-clinical data and multi‑time point biodistribution data.
Our approach follows FDA, EMA and MHRA guidance for radiopharmaceuticals, giving innovators the confidence to progress toward IND and first‑in‑human studies.
One team. One workflow. One standard of quality.
If you need dosimetry that stands up to regulators and investors, you need us.
In the complex landscape of radiochemistry and translational imaging, the difference lies in the expertise behind the science.
Our team comprises industry-leading specialists across preclinical services and radiopharmaceuticals, dedicated to bridging the gap between early discovery and clinical success.
Meet the experts who turn sophisticated data into actionable therapeutic insights.
Explore our scientific expertiseBrief: Determine human organ dose exposure for IND planning.
We delivered:
Outcome: IND‑enabling package strengthened and timelines protected.
Ready to accelerate your dosimetry project?
Our experts are here to support your journey from concept to clinic. Contact our team to discuss a tailored solution.
Speak to the team, we’ll scope your project and get you moving fast.
